Fundraising Fox
🦊/Companies
Sign in

Rakuten Med

San Diego, US · Founded 2010 · 1 known investors

Find your way into Rakuten Med

736 people in our graph share verified history with the Rakuten Med team — schools, employers, funds. One of them is your warm intro.

Paul Kwanunlockedknows Tiffany Piecewicz · together at Rakuten Med (overlapped)
×3knows the team · via University of Southern California
knows the team · via The Johns Hopkins University
knows the team · via Food 52
×3knows the team · via University of Phoenix
knows the team · via Amgen

Rakuten Medical is a global biotechnology company that develops and commercializes precision cell-targeting photoimmunotherapy treatments for cancer using its proprietary Alluminox platform. The company focuses on creating innovative cancer treatment options and bringing them to patients worldwide.

BiotechHealthtechMedical Devices

Founders & leadership

ABAbhijit Bhatia
Abhijit BhatiainChief Operating Officer (COO)Abhijit Bhatia is an executive officer at Rakuten Medical, a biotechnology company developing precision cell-targeting photoimmunotherapy cancer treatments using its Alluminox platform. He brings expertise in business strategy, corporate partnerships, deal negotiation, and commercialization within the life sciences sector.
TP
Tiffany PiecewiczinGeneral CounselTiffany Piecewicz is an attorney with 15+ years of experience in corporate governance, intellectual property litigation, employment law, and contract disputes across multinational organizations. She has managed strategic matters for cases valued up to $14B and has worked on international corporate compliance projects in Europe.
SS
Suzane SaninChief People OfficerSuzane San is an Executive Officer at Rakuten Medical with over 15 years of experience in people operations and organizational development within the biotechnology sector. Her background includes designing and implementing HR programs, advising on personnel matters, and supporting organizational growth across biotech companies.
MGMiguel Garcia-Guzman
Miguel Garcia-GuzmaninBoard Member
MM
Minami MaedaExecutive
TSToshiaki Suzuki
Toshiaki SuzukiinSenior Director
SSScott Salka
Scott SalkainChief Executive Officer2010–2015
HM
Hiroshi MikitaniNamed on SEC filing

Board

DC
David ChaoBoard director
MD
Mazen DarwazahBoard director
HM
Hiroshi MoriBoard director
EK
Eiichi KagaBoard director

Investors · 1

Taiwania CapitalTaipei · $3M – $85M

Reported raises · per SEC filings

Form D private placements

$899.3M disclosed across 16 rounds · 2014–2025

▶$111.5MraisedApr 2026 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Hiroshi MoriDirector
  • Hiroyuki KodamaExecutive Officer
  • Hiroshi MikitaniExecutive Officer, Director
  • Suzane SanExecutive Officer
  • David ChaoDirector
  • Toshiaki SuzukiExecutive Officer
  • Carlos GarciaExecutive Officer
  • Maeda MinamiExecutive Officer
  • Abhijit BhatiaExecutive Officer
  • Kentaro HyakunoDirector
  • Nitin NohriaDirector
  • Mazen DarwazahDirector
  • Eiichi KagaDirector
  • Miguel Garcia-GuzmanDirector
  • Tiffany PiecewiczExecutive Officer
Offering amount
$116.7M
Amount sold
$111.5M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.9MraisedMay 2025 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Abhijit BhatiaExecutive Officer
  • Nitin NohriaDirector
  • David ChaoDirector
  • Tiffany PiecewiczExecutive Officer
  • Mazen DarwazahDirector
  • Suzane SanExecutive Officer
  • Hiroshi MikitaniExecutive Officer, Director
  • Hiroshi MoriDirector
  • Miguel Garcia-GuzmanDirector
  • Eiichi KagaDirector
  • Minami MaedaExecutive Officer
  • Toshiaki SuzukiExecutive Officer
  • Carlos GarciaExecutive Officer
  • Kentaro HyakunoDirector
Offering amount
$1.9M
Amount sold
$1.9M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.2MraisedMar 2024 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David ChaoDirector
  • Carlos GarciaExecutive Officer
  • Mazen DarwazahDirector
  • Suzane SanExecutive Officer
  • Hiroshi MoriDirector
  • Hiroshi MikitaniExecutive Officer, Director
  • Kentaro HyakunoDirector
  • Hiroshi TakasawaDirector
  • Nitin NohriaDirector
  • Miguel Garcia-GuzmanDirector
  • Takashi ToraishiExecutive Officer, Director
  • Abhijit BhatiaExecutive Officer
  • Agatha MartindaleExecutive Officer
  • Minami MaedaExecutive Officer
  • Tiffany PiecewiczExecutive Officer
  • Toshiaki SuzukiExecutive Officer
Offering amount
$4.2M
Amount sold
$4.2M
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedOct 2023 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kentaro HyakunoDirector
  • Mazen DarwazehDirector
  • Hiroshi MoriDirector
  • Nitin NohriaDirector
  • David ChaoDirector
  • Toshiaki SuzukiExecutive Officer
  • Takashi ToraishiExecutive Officer, Director
  • Abhijit BhatiaExecutive Officer
  • Tiffany PiecewiczExecutive Officer
  • Hiroshi TakasawaDirector
  • Hiroshi MikitaniExecutive Officer, Director
  • Miguel Garcia-GuzmanDirector
  • Carlos GarciaExecutive Officer
Offering amount
$2.2M
Amount sold
$2.2M
First sale
Jun 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$104.8MraisedSep 2023 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tiffany PiecewiczExecutive Officer
  • Miguel Garcia-GuzmanDirector
  • Nitin NohriaDirector
  • David ChaoDirector
  • Carlos GarciaExecutive Officer
  • Mazen DarwazehDirector
  • Takashi ToraishiExecutive Officer, Director
  • Kentaro HyakunoDirector
  • Hiroshi MikitaniExecutive Officer, Director
  • Abhijit BhatiaExecutive Officer
  • Hiroshi MoriDirector
  • Hiroshi TakasawaDirector
Offering amount
$123.7M
Amount sold
$104.8M
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$70MraisedDec 2022 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Miguel Garcia-GuzmanDirector
  • Carlos GarciaExecutive Officer
  • Tiffany PiecewiczExecutive Officer
  • Hiroshi MoriDirector
  • David ChaoDirector
  • Kentaro HyakunoDirector
  • Abhijit BhatiaExecutive Officer
  • Takashi ToraishiExecutive Officer, Director
  • Nitin NohriaDirector
  • Hiroshi MikitaniExecutive Officer, Director
  • Hiroshi TakasawaDirector
Offering amount
$90M
Amount sold
$70M
First sale
Dec 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$166MraisedJul 2021 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Miguel Garcia-GuzmanExecutive Officer, Director
  • David ChaoDirector
  • Takashi ToraishiExecutive Officer, Director
  • Kentaro HyakunoDirector
  • Ann McGuireExecutive Officer
  • Hiroshi MoriDirector
  • Carlos GarciaExecutive Officer
  • Hiroshi TakasawaDirector
  • Nitin NohriaDirector
  • Hiroshi MikitaniExecutive Officer, Director
Offering amount
$291M
Amount sold
$166M
Sales commissions
$3M
Placement agents
TAP Securities LLC, Momentum Capital Markets, LLC
First sale
Jul 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedJan 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Miguel Garcia-GuzmanExecutive Officer, Director
  • Takashi ToraishiExecutive Officer, Director
  • Hiroshi MikitaniExecutive Officer, Director
  • Brenton KeathExecutive Officer
  • Carlos GarciaExecutive Officer
  • David ChaoDirector
  • Kentaro HyakunoDirector
  • Hiroshi MoriDirector
Offering amount
$15M
Amount sold
$15M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
MD Anderson Cancer Center15 shared keywordsUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
Globaldata15 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Bioworld15 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Kura Oncology14 shared keywordsKura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

Companies competing with Rakuten Med for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Rakuten Med do?
Rakuten Medical is a global biotechnology company that develops and commercializes precision cell-targeting photoimmunotherapy treatments for cancer using its proprietary Alluminox platform. The company focuses on creating innovative cancer treatment options and bringing them to patients worldwide.
Who are Rakuten Med's investors?
Rakuten Med's investors include Taiwania Capital.
How much funding has Rakuten Med raised?
Rakuten Med has disclosed $899.3M raised across 16 rounds.
Where is Rakuten Med headquartered?
Rakuten Med is headquartered in San Diego, US.